Truist Maintains Buy Rating on Nurix Therapeutics, Keeps $33 Target
Truist Securities maintained its Buy rating and $33 price target on Nurix Therapeutics. The target implies 48.9% upside from the Oct. 12 close of $22.16.
Truist Securities maintained its Buy rating and $33 price target on Nurix Therapeutics. The target implies 48.9% upside from the Oct. 12 close of $22.16.